OXFORD & NEWCASTLE, England--(BUSINESS WIRE)--e-Therapeutics plc today announces that the investigator-led phase I trial of ETS2101 in brain cancer will continue into 2014. Five dose escalation steps have been completed without any drug-related serious adverse events and the investigator therefore intends to enrol further patients at higher dose levels.
Help employers find you! Check out all the jobs and post your resume.
